ReviewOncogene2006
Proteomics for the early detection and treatment of hepatocellular carcinoma.
Review in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Plasma proteomic profiling reveals distinct protein signatures associated with hepatocellular carcinoma in chronic hepatitis B infection.Clinical proteomics · 2026Article
- Strategies for discovering novel hepatocellular carcinoma biomarkers.World journal of hepatology · 2025Review
- Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma.Biomedicines · 2025Article
- A deep learning framework for hepatocellular carcinoma diagnosis using MS1 data.Scientific reports · 2024Article
- Dysregulation of miR-3607 predicts prognosis of hepatocellular carcinoma and regulates tumor cell proliferation, migration and invasion.Diagnostic pathology · 2020Article
- Application of Proteomics to Inflammatory Bowel Disease Research: Current Status and Future Perspectives.Gastroenterology research and practice · 2019Review
- Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372.Oncotarget · 2017Article
- Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma.BMC cancer · 2015Article
- Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies.World journal of gastroenterology · 2014Review
- Proteome Analyses of Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2014Review
- miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis.BMC cancer · 2014Article
- Loss of expression of MHC class I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma.International journal of clinical and experimental pathology · 2014Article
- Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma.PloS one · 2013Article
- Current advantages in the application of proteomics in inflammatory bowel disease.Digestive diseases and sciences · 2012Review
- Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients.Journal of Cancer · 2012Article
- Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma.Journal of biosciences · 2011Article
- Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery.Cancer letters · 2009Review
- Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues.Journal of experimental & clinical cancer research : CR · 2009Article
- Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies.Inflammatory bowel diseases · 2009Review
- Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma.Journal of proteome research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis for hepatocellular carcinoma (HCC) is poor and has not improved in recent years, largely owing to lack of early diagnosis, frequent recurrence after surgery and resistance to chemotherapy. Proteomics holds the promise of improving our understanding of HCC carcinogenesis and progression as well as of discovering novel diagnostics and therapeutics. Proteomic analyses of HCC cell lines, animal models and serum and tumor tissue from patients with HCC have been performed to date. Proteomic technologies have greatly improved in the past few years as reviewed here. It is anticipated that with the recent development of protein tagging, protein separation methods and mass spectrometry sensitivity, proteomic studies of HCC will allow the identification of diagnostic and prognostic biomarkers as well as therapeutic targets, which could greatly improve the clinical management of HCC patients.
Indexed as
Identifiers
16799622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.